The metastasis of chromophobe renal cell carcinoma to head and neck region, described herein, has never been reported before to our knowledge. A 56-year-old woman with a history of nephrectomy, that revealed chromophobe renal cell carcinoma six years before, presented left cervical mass. Imaging showed with left cervical lymphadenopathies and thyroid nodule. Surgery with histopathological examination confirmed that it was a left central and lateral jugular lymph node metastasis of chromophobe renal cell carcinoma treated postoperatively by antiangiogenic therapy. The patient was successfully treated by surgery and antiangiogenic drugs with stabilization and no recurrence of the metastatic disease. The case and the literature reported here support that chromophobe renal cell carcinoma can metastasize to the head and neck region and should preferentially be treated with surgery and antiangiogenic therapy because of the associated morbidity and quality-of-life issues. 1. Introduction Renal cell carcinoma represents 3% of all adult malignant tumors [1]. Chromophobe renal cell carcinoma is a unique and infrequent subtype that comprises approximately 3% to 5% of all hypernephromas [2]. Although renal cell carcinoma is the third most common infraclavicular neoplasm that metastasizes to the head and neck region. Liver and lung are the most common sites of metastasis for chromophobe renal cell carcinoma that has better prognosis and lower potential to metastasize than the other subtypes of the hypernephroma [3, 4]. This case report and review of the literature describes a cervical lymph node metastasis in chromophobe renal cell carcinoma that has never been reported before in a large database search. 2. Patient and Methods A 56-year-old female was admitted, in November 2011, to our department with a complaint of masse in her left neck region gradually evolved since 7 months with palpitations. The patient is asthmatic treated by Salbutamol, is hypertense with no treatment followed since 2009, and is treated for pulmonary tuberculosis 33 years ago. The past medical history of the patient included a left nephrectomy without therapeutic supplement in 2006 for renal tumoral syndrome revealed by left chronic lumbar pains. The pathological analysis revealed chromophobe renal cell carcinoma, T2N0Mx stage II, Fuhrman nuclear grade 2, and no sarcomatoid or papillary or tumor necrosis components were identified. A physical examination of the patient showed a painless left cervical masse; its greatest diameter is 04？cm with hard consistency. The thyroid function tests were
References
[1]
A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA: Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009.
[2]
T. B. Crotty, G. M. Farrow, and M. M. Lieber, “Chromophobe cell renal carcinoma: clinicopathological features of 50 cases,” Journal of Urology, vol. 154, no. 3, pp. 964–967, 1995.
[3]
P. M. Som, K. I. Norton, J. M. Shugar et al., “Metastatic hypernephroma to the head and neck,” The American Journal of Neuroradiology, vol. 8, no. 6, pp. 1103–1106, 1987.
[4]
M. B. Amin, G. P. Paner, I. Alvarado-Cabrero et al., “Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases,” The American Journal of Surgical Pathology, vol. 32, no. 12, pp. 1822–1834, 2008.
[5]
D. G. Bostwick and J. N. Eble, “Diagnosis and classification of renal cell carcinoma,” Urologic Clinics of North America, vol. 26, no. 3, pp. 627–635, 1999.
[6]
M. ？zkiri？, U. Kubilay, and O. S. Sezen, “Cervical lymph node metastasis in renal cell carcinoma,” Journal of Oral and Maxillofacial Pathology, vol. 15, no. 2, pp. 211–213, 2011.
[7]
W. Thoenes, S. St？rkel, and H. J. Rumpelt, “Human chromophobe cell renal carcinoma,” Virchows Archiv Abteilung B, vol. 48, no. 3, pp. 207–217, 1985.
[8]
T. Klatte, K. Han, J. W. Said et al., “Pathobiology and prognosis of chromophobe renal cell carcinoma,” Urologic Oncology: Seminars and Original Investigations, vol. 26, no. 6, pp. 604–609, 2008.
[9]
M. Akhtar, T. Linjawi, J. McClintock, H. Kardar, and M. A. Ali, “Chromophobe cell carcinoma of the kidney: a clinicopathologic study of 21 cases,” The American Journal of Surgical Pathology, vol. 19, no. 11, pp. 1245–1256, 1995.
[10]
L. Cindolo, A. de la Taille, L. Schips et al., “Chromophobe renal cell carcinoma: comprehensive analysis of 104 cases from multicenter European database,” Urology, vol. 65, no. 4, pp. 681–686, 2005.
[11]
S. D. W. Beck, M. I. Patel, M. E. Snyder et al., “Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma,” Annals of Surgical Oncology, vol. 11, no. 1, pp. 71–77, 2004.
[12]
K. M. Pritchyk, B. A. Schiff, K. A. Newkirk, E. Krowiak, and Z. E. Deeb, “Metastatic renal cell carcinoma to the head and neck,” Laryngoscope, vol. 112, no. 9, pp. 1598–1602, 2002.
[13]
M. Peyromaure, N. Thiounn, A. Vieillefond, et al., “Cancer du rein à cellules chromophobes, une entité à part entière. A propos d’une série de 35 cas,” Progrès en Urologie, vol. 11, pp. 209–216, 2001.
[14]
S. E. Eggener, O. Yossepowitch, S. Kundu, R. J. Motzer, and P. Russo, “Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma,” Journal of Urology, vol. 180, no. 3, pp. 873–878, 2008.
[15]
R. Stec, B. Grala, M. M？cZewski, L. Bodnar, and C. Szczylik, “Chromophobe renal cell cancer—review of the literature and potential methods of treating metastatic disease,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 134, 2009.
